Global Blood Therapeutics Inc
$
57.92
0.01 (0.01%)
| Volume: | 79,994 | Avg Vol (1m): | 945,028 |
| Market Cap $: | 3.43 Bil | Enterprise Value $: | 2.97 Bil |
| P/E (TTM): | 0.00 | P/B: | 5.74 |
| Earnings Power Value | 7.71 |
| Net Current Asset Value | 7.27 |
| Tangible Book | 9.9 |
| Projected FCF | 0 |
| Median P/S Value | 0 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 8.2/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | No Debt | N/A | |
| Interest Coverage | No Debt | N/A | |
| Piotroski F-Score | 3 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 30.18 |
DISTRESS
GREY
SAFE
| |
| WACC vs ROIC % |
ROIC -299.25%
WACC 9.21%
| ||
Profitability & Growth : 3/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| ROE % | -34.31 |
ROE range over the past 10 years
Min: -101.37, Med: -48.38, Max: -34.31
Current: -34.31
| |
| ROA % | -31.81 |
ROA range over the past 10 years
Min: -293.52, Med: -45.59, Max: -31.81
Current: -31.81
| |
| ROC (Joel Greenblatt) % | -1213.71 |
ROC (Joel Greenblatt) range over the past 10 years
Min: -3666.83, Med: -1207.08, Max: -640.91
Current: -1213.71
| |
| 3-Year Total EBITDA Growth Rate | -57.60 |
3-Year EBITDA Growth Rate range over the past 10 years
Min: -54.4, Med: -45.9, Max: 0.7
Current: 0.7
| |
| 3-Year EPS w/o NRI Growth Rate | 4.80 |
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -22.3, Max: 4.8
Current: 4.8
|
» GBT's 30-Y Financials
Financials (Next Earnings Date: 2019-08-02)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:GBT
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology NAICS : 325411 SIC : 2834 |
| Compare | TSE:4974 NAS:ONCE NAS:AKCA XKRX:006280 SZSE:300294 NAS:IMMU NAS:RARE NAS:CRSP NYSE:XON XSWX:GALE ROCO:4147 NAS:DNLI LSE:GNS SZSE:002821 XMCE:ALM NAS:PTLA XBRU:ARGX NAS:CORT SZSE:002287 NYSE:EBS |
| Traded in other countries | G5B.Germany 0IVZ.UK |
| Address | 171 Oyster Point Boulevard, Suite 300, South San Francisco, CA, USA, 94080 |
| Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 5.76 |
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 11.15
Current: 5.76
| |
| EV-to-EBIT | -14.46 |
EV-to-EBIT range over the past 10 years
Min: -27.26, Med: 0, Max: 0
Current: -14.46
| |
| EV-to-EBITDA | -14.98 |
EV-to-EBITDA range over the past 10 years
Min: -27.65, Med: 0, Max: 0
Current: -14.98
| |
| Current Ratio | 14.51 |
Current Ratio range over the past 10 years
Min: 0.99, Med: 14.51, Max: 24.45
Current: 14.51
| |
| Quick Ratio | 14.51 |
Quick Ratio range over the past 10 years
Min: 0.99, Med: 14.51, Max: 24.45
Current: 14.51
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -20.30 |
3-Year Share Buyback Rate range over the past 10 years
Min: -28.6, Med: -20.3, Max: -18.9
Current: -20.3
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 5.81 |
Price-to-Tangible-Book range over the past 10 years
Min: 2.69, Med: 4.63, Max: 8.29
Current: 5.81
| |
| Earnings Yield (Joel Greenblatt) % | -6.95 |
Earnings Yield (Greenblatt) range over the past 10 years
Min: -266.48, Med: 0, Max: 0
Current: -6.95
|
More Statistics
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 3 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | N |